Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Bone marrow monocyte PECAM-1 deficiency elicits increased osteoclastogenesis resulting in trabecular bone loss.

Wu Y, Tworkoski K, Michaud M, Madri JA.

J Immunol. 2009 Mar 1;182(5):2672-9. doi: 10.4049/jimmunol.0802398.

2.
3.

The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: increased resorption and osteopenia in me(v)/me(v) mutant mice.

Aoki K, Didomenico E, Sims NA, Mukhopadhyay K, Neff L, Houghton A, Amling M, Levy JB, Horne WC, Baron R.

Bone. 1999 Sep;25(3):261-7.

PMID:
10495129
5.

IL-1 plays an important role in the bone metabolism under physiological conditions.

Lee YM, Fujikado N, Manaka H, Yasuda H, Iwakura Y.

Int Immunol. 2010 Oct;22(10):805-16. doi: 10.1093/intimm/dxq431. Epub 2010 Aug 2.

6.

BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.

Valverde P, Tu Q, Chen J.

J Bone Miner Res. 2005 Sep;20(9):1669-79. Epub 2005 May 16.

7.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

8.

Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.

Hasegawa H, Kido S, Tomomura M, Fujimoto K, Ohi M, Kiyomura M, Kanegae H, Inaba A, Sakagami H, Tomomura A.

J Biol Chem. 2010 Aug 13;285(33):25448-57. doi: 10.1074/jbc.M109.068742. Epub 2010 Jun 14.

9.

Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption.

Peng S, Liu XS, Zhou G, Li Z, Luk KD, Guo XE, Lu WW.

J Bone Miner Res. 2011 Jun;26(6):1272-82. doi: 10.1002/jbmr.325.

10.

Deficiency of chemokine receptor CCR1 causes osteopenia due to impaired functions of osteoclasts and osteoblasts.

Hoshino A, Iimura T, Ueha S, Hanada S, Maruoka Y, Mayahara M, Suzuki K, Imai T, Ito M, Manome Y, Yasuhara M, Kirino T, Yamaguchi A, Matsushima K, Yamamoto K.

J Biol Chem. 2010 Sep 10;285(37):28826-37. doi: 10.1074/jbc.M109.099424. Epub 2010 Jun 22.

11.

Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.

Hayashi S, Yamada T, Tsuneto M, Yamane T, Takahashi M, Shultz LD, Yamazaki H.

J Immunol. 2003 Nov 15;171(10):5130-9.

12.

Ameloblastin modulates osteoclastogenesis through the integrin/ERK pathway.

Lu X, Ito Y, Atsawasuwan P, Dangaria S, Yan X, Wu T, Evans CA, Luan X.

Bone. 2013 May;54(1):157-68. doi: 10.1016/j.bone.2013.01.041. Epub 2013 Feb 4.

PMID:
23385480
13.

T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy.

Lee SK, Kadono Y, Okada F, Jacquin C, Koczon-Jaremko B, Gronowicz G, Adams DJ, Aguila HL, Choi Y, Lorenzo JA.

J Bone Miner Res. 2006 Nov;21(11):1704-12.

14.

Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption.

Xing L, Carlson L, Story B, Tai Z, Keng P, Siebenlist U, Boyce BF.

J Bone Miner Res. 2003 Feb;18(2):260-9.

15.

Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice.

Ueki Y, Lin CY, Senoo M, Ebihara T, Agata N, Onji M, Saheki Y, Kawai T, Mukherjee PM, Reichenberger E, Olsen BR.

Cell. 2007 Jan 12;128(1):71-83.

16.

Protein tyrosine phosphatases in osteoclast differentiation, adhesion, and bone resorption.

Granot-Attas S, Elson A.

Eur J Cell Biol. 2008 Sep;87(8-9):479-90. doi: 10.1016/j.ejcb.2008.01.006. Epub 2008 Mar 14. Review.

PMID:
18342392
18.

Suppressors of cytokine signaling-1 and -3 regulate osteoclastogenesis in the presence of inflammatory cytokines.

Ohishi M, Matsumura Y, Aki D, Mashima R, Taniguchi K, Kobayashi T, Kukita T, Iwamoto Y, Yoshimura A.

J Immunol. 2005 Mar 1;174(5):3024-31.

19.

Deficiency of SHP-1 protein-tyrosine phosphatase activity results in heightened osteoclast function and decreased bone density.

Umeda S, Beamer WG, Takagi K, Naito M, Hayashi S, Yonemitsu H, Yi T, Shultz LD.

Am J Pathol. 1999 Jul;155(1):223-33.

20.

Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development.

Mori Y, Tsuji S, Inui M, Sakamoto Y, Endo S, Ito Y, Fujimura S, Koga T, Nakamura A, Takayanagi H, Itoi E, Takai T.

J Immunol. 2008 Oct 1;181(7):4742-51.

Items per page

Supplemental Content

Write to the Help Desk